Anaphylaxis is a medical condition in which serious allergic conditions occur that may cause death of patient. Itchy rash, throat swelling, shortness of breath, vomiting, and low blood pressure are some symptoms of anaphylaxis. Moreover, it can cause cardiovascular, respiratory, gastrointestinal, and cutaneous manifestations result in death of patient. Insect bites, unwanted food consumption, and medication are common causes of anaphylaxis. Anaphylaxis is diagnosed on the basis of patient symptoms. Primary treatment of anaphylaxis consist of epinephrine injection into the muscle, then placing person with elevated feet to restore normal blood flow. Epinephrine auto-injector is suggested for the people who have anaphylaxis history. Other medication include anti-histamine and steroids are complementary.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the anaphylaxis treatment market.
Top Impacting Factors
- Surge in incidence of anaphylaxis across the globe, increase in awareness regarding available treatments, rise in patients suffering from allergies, surge in geriatric population, and rise in overuse of medicines in rural areas are the key factors that drive the growth of market.
- In addition, continuous strategic developments & promising product launches by key market players, emerging advanced technologies in developing countries, increase in demand for self-administrating treatments, R&D activities to improve quality of drugs, launch of novel drug treatment, rise in demand for cost effective treatment, and increase in demand for minimally invasive treatment can boost the growth of anaphylaxis treatment market.
- However, lack of awareness in developing region and side effects elated to use of steroids & epinephrine can hinder the growth of market.
- Contrarily, government initiatives to reduce cost of treatment and increase in number of product approvals are expected to offer lucrative opportunities for the expansion of the market.
Market Trend
New Product Launches to Flourish the Market
In 2020, Bausch Health announced launch of Emerade in Canada. Emerade is a 0.3mg and 0.5 mg dose auto-injector use in treatment of anaphylaxis.
In 2019, Sandoz Inc. announced launch of SYMJEPI in U.S. This is a 0.3mg epinephrine injection for emergency treatment of allergic reaction including anaphylaxis.
In 2018, Teva Pharmaceutical received FDA approval for launch of epinephrine auto-injector. This was the first generic auto-injector equivalent to EpiPen which is an emergency injectable for anaphylaxis treatment.
Key Benefits of the Report
- This study presents the analytical depiction of anaphylaxis treatment market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Anaphylaxis Treatment Market Report
- Which are the leading players active in the anaphylaxis treatment market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "anaphylaxis treatment"?
- What is "anaphylaxis treatment" market prediction in the future?
- Who are the leading global players in the "anaphylaxis treatment" market?
- What are the current trends and predicted trends?
- What are the key benefits of the "anaphylaxis treatment" market report?
Anaphylaxis Treatment Market Report Highlights
| Aspects | Details |
 By Drug Class |
|
 By Route of Administration |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Adamis Pharmaceutical Corporation, Mylan N.V., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., ALK-Abelló., MannKind Corporation, Lincoln Medical Ltd., Impax Laboratories Inc., GlaxoSmithKline Plc., Pfizer Inc |
Loading Table Of Content...
